Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Corvus Pharma Com (CRVS)

4.02   0.34 (9.24%) 08-14 16:00
Open: 3.76 Pre. Close: 3.68
High: 4.194 Low: 3.6261
Volume: 390,172 Market Cap: 113M
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.192 - 4.217 4.217 - 4.242
Low: 3.577 - 3.603 3.603 - 3.629
Close: 3.976 - 4.018 4.018 - 4.059

Technical analysis

as of: 2020-08-14 4:28:44 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.31     One year: 6.06
Support: Support1: 3.50    Support2: 2.91
Resistance: Resistance1: 4.54    Resistance2: 5.19
Pivot: 4.11
Moving Average: MA(5): 3.97     MA(20): 4.20
MA(100): 3.29     MA(250): 3.59
MACD: MACD(12,26): 0.03     Signal(9): 0.11
Stochastic oscillator: %K(14,3): 20.92     %D(3): 16.95
RSI: RSI(14): 49.90
52-week: High: 6.88  Low: 1.01  Change(%): -4.3
Average Vol(K): 3-Month: 218121  10-Days: 30929

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
CRVS has closed above bottom band by 36.7%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to CRVS's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 12 Aug 2020
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Becomes The New Buzzing Stock: Sports A Monthly Volatility Of 9.62% - The Comet Reports

Tue, 04 Aug 2020
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference - Yahoo Finance

Mon, 03 Aug 2020
How Much Of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Do Insiders Own? -

Sun, 02 Aug 2020
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha

Thu, 30 Jul 2020
Corvus: 2Q Earnings Snapshot - San Francisco Chronicle

Wed, 29 Jul 2020
Corvus Pharmaceuticals Inc. (CRVS) Soars 6.12% on July 29 -

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 28
Shares Float (M) 14
% Held by Insiders 6.31
% Held by Institutions 75.64
Shares Short (K) 424
Shares Short P. Month (K) 328

Stock Financials

EPS -1.633
EPS Est This Year -3.180
EPS Est Next Year -3.410
Book Value (p.s.) 2.150
Profit Margin
Operating Margin
Return on Assets (ttm) -33.5
Return on Equity (ttm) -59.7
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.756
Qtrly Earnings Growth
Operating Cash Flow (M) -38
Levered Free Cash Flow (M) -20

Stock Valuations

PE Ratio -2.46
PEG Ratio
Price to Book value 1.87
Price to Sales
Price to Cash Flow -2.98

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.